Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05885828

The PRECISION-T2D Study: Precision Nutrition Study for Type 2 Diabetes

Food plays a crucial role in determining blood glucose levels, especially in people with type 2 diabetes. Precision nutrition, which involves individually tailored dietary interventions, can be a powerful tool in managing blood glucose levels in people with type 2 diabetes. Previous studies found that changes in gut microbiota resulted from the dietary intervention, such as plant-based diet, might subsequently lead to different glycemic responses, and then different health outcomes.

In this study, the investigators will characterize the blood glucose dynamics and gut microbiota of individuals with type 2 diabetes. They aim to assess the influence of plant-based diet on gut microbiota; they will also investigate the influence of gut microbiota on glycemic responses. Additionally, a series of individual N-of-1 trails will be integrated to compare the effects of a white bread breakfast and a whole wheat bread breakfast on glucose metabolism at the individual level.

Recruiting

Interested in participating?

Request Info

Key information

Age range

35 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Hangzhou Third People's Hospital, Hangzhou, Zhejiang, China

Loading trial locations.

About this study

Choice of design: The study is a two-arm intervention study integrated with N-of-1 design.

Study population: Patients with type 2 diabetes.

Screening Assessment: Prospective participants will be selected based on the pre-defined inclusion and exclusion criteria. Recruitment will be done over the phone and via the social media.

Study duration: Each participant will take part in the study for a period of up to 1 month at baseline and have follow-up visits every 1-2 years.

Dietary intervention:

The PRECISION-T2D is a dietary intervention study. Upon admission, patients will be randomly assigned to two groups: plant-based diet and conventional diabetic diet. Throughout the hospitalization, all participants (n=200) will be given standardized meals. A dietitian will design the diet for both plant-based and conventional diabetic diet groups following 2023 Chinese Diabetes Society guidelines. Both diets comprised approximately 50-65% of energy from carbohydrates, 20-30% of energy from fat, 15-20% from protein. The plant-based diet had higher fiber content (25-30g) compared to the conventional diabetic diet (15-20g). Participants will be asked to consume the entire amount of food indicated for the standardized meals and to record any leftover food. All participants will be asked to track their meals, snacks and drinks with instructions on how to record their daily dietary information. Participants will also be advised not to modify their exercise habits during the course of the study. Upon discharge, Participants in the plant-based diet arm will be recommended to consume more fiber-rich foods, including whole grains, fruits, legumes and vegetables; to moderate their intake of fish, eggs and dairy products; and to avoid other animal products. Participants in the conventional diabetic diet arm will be recommended to have a diet following 2023 Chinese Diabetes Society guidelines. Individual N-of-1 trial design will be employed to all participants during day one to day twelve to compare the difference of postprandial glucose response to white bread or whole wheat bread. These two standard breakfasts will appear in pseudo-random order. During the participants' first baseline visit day, they will be asked to complete a baseline questionnaire to collect information on their lifestyle, dietary habits, history of medications, sleep quality and appetite. Anthropometric measurements, ultrasonography evaluation, and laboratory tests will be taken using standard protocols. Participants will then be asked to wear a continuous glucose monitor (CGM) for 14-day blood glucose monitoring, which will be done by a nurse. On day 14, participants will be asked to come in for a clinical visit where they will receive their CGM report and provide blood, saliva, urine and stool samples. On day 30, participants will be asked to come in for another clinical visit where they will provide blood, saliva, urine and stool samples.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Diagnosed with type 2 diabetes;
  • Living in Hangzhou for at least five years;
  • Have the willingness or ability to complete the intervention and sample collection

Exclusion criteria

  • Mental and physical disability;
  • Already is a vegetarian;
  • Cancer and serious complications from type 2 diabetes, such as renal failure;
  • Using insulin for more than 5 years;
  • Unstable medical/medication status;
  • Current alcohol or drug abuse;
  • Taking antibiotics in the last three months

Treatment and study plan

White Bread

Other

After wearing CGM on Day 1, participants will be provided with white bread (76-77g) and milk (250mL) for breakfast on Day 3, Day 4, Day 7, Day 8, Day 10, Day 12.

Other names: Breakfast A

Whole wheat bread

Other

After wearing CGM on Day 1, participants will be provided with wheat bread (85-86g) and milk (250mL) for breakfast on Day 2, Day 5, Day 6, Day 9, Day 11, Day 13.

Other names: Breakfast B

Plant-based diet

Behavioral

After wearing CGM on Day 1, participants will be asked to follow the plant-based diet in next 30 days.

Conventional diabetic diet

Other

Volunteers will be asked to have a diet following 2023 Chinese Diabetes Society guidelines in next 30 days.

Follow-up visit every 1-2 years

Other

Participants will be visited every 1-2 years. At each visit, face-to-face interviews, specimen collection, anthropometric measurements, ultrasonography evaluation, laboratory tests, and multi-omics data will be conducted.

Primary outcomes

  1. Changes in gut microbiome profile

    Time frame: Day 1 and Day 31

    Shotgun metagenomic sequencing will be performed in stool samples.

  2. Blood glucose profile

    Time frame: 2 weeks

    Real-time blood glucose fluctuations will be recorded using continuous glucose monitoring.

Secondary outcomes

  1. Carotid plaque

    Time frame: At enrollment

    Grade carotid plaque using ultrasound.

  2. Carotid intima-media thickness

    Time frame: At enrollment

    Measure of carotid intima-media thickness using ultrasound.

  3. Number of participants with chronic kidney disease

    Time frame: Up to 10 years

    The serum creatine and urine creatine and protein will be measured and chronic kidney disease will be defined as an estimated glomerular filtration rate of <60 mL/min/1.73 m2 or and the presence of an elevated urine microalbumin/creatinine ratio. All cases will be verified by medical record review.

  4. Cognitive function

    Time frame: Up to 10 years

    Cognitive function was measured by the Addenbrooke's Cognitive Examination-Revised (ACE-R). The original 26 components were combined to produce five subscores, 100 in total. The cutoff for dementia is 82-88/100.

  5. Changes in fasting blood glucose

    Time frame: Day 1 and Day 31

    Fasting glucose will be examined in mmol/L.

  6. Changes in fasting blood C-peptide

    Time frame: Day 1 and Day 31

    Fasting blood C-peptide will be examined in μg/L.

  7. Changes in fasting blood HbA1c

    Time frame: Day 1 and Day 31

    Fasting blood HbA1c will be examined in %.

  8. Changes in lipid metabolism

    Time frame: Day 1 and Day 31

    Triglyceride, cholesterol, high density lipoprotein cholesterol and low density lipoprotein cholesterol will be examined in mmol/L.

Study contacts

Contact information is provided by the study sponsor or research team.

Ju-Sheng Zheng, PhD

CONTACT

[email protected]

86-0571-88112056

Sponsors and collaborators

Lead sponsor

Westlake University

Other

Collaborators

  • The Third People's Hospital of Hangzhou

Registry information

Important dates

Study start
2023
Primary completion
2025
Study completion
2033
First posted
Jun 2, 2023
Registry last updated
Jun 13, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.